IMRN Key Statistics, Chart & Performance
The current stock price of IMRN is 0.97 USD. In the past month the price increased by 7.59%. In the past year, price decreased by -53.37%.
IMRN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to IMRN. When comparing the yearly performance of all stocks, IMRN is a bad performer in the overall market: 95.5% of all stocks are doing better.
IMRN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMRN. While IMRN seems to be doing ok healthwise, there are quite some concerns on its profitability.
IMRN Financial Highlights
Over the last trailing twelve months IMRN reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS increased by 25.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -51.49% | ||
| ROE | -64.64% | ||
| Debt/Equity | 0 |
IMRN Forecast & Estimates
IMRN Ownership
About IMRN
Company Profile
Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. The company operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), and IMM-529.
Company Info
IMMURON LTD-SPON ADR
62 Lygon Street, Level 3
Melbourne VICTORIA 3053 AU
CEO: Jerry Kanellos
Employees: 6
Phone: 61398245254
IMMURON LTD-SPON ADR / IMRN FAQ
What does IMRN do?
Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. The company operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), and IMM-529.
What is the current price of IMRN stock?
The current stock price of IMRN is 0.97 USD. The price increased by 2.11% in the last trading session.
What is the dividend status of IMMURON LTD-SPON ADR?
IMRN does not pay a dividend.
How is the ChartMill rating for IMMURON LTD-SPON ADR?
IMRN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is IMMURON LTD-SPON ADR worth?
IMMURON LTD-SPON ADR (IMRN) has a market capitalization of 7.84M USD. This makes IMRN a Nano Cap stock.